OH-UWL
26.4.2022 19:42:09 CEST | Business Wire | Press release
UWL, a top 10 American-owned NVOCC and leading provider of global 3PL services, has contracted with Swire Shipping, a multi-purpose liner service, to launch a new, exclusive express service, departing from Ho Chi Minh City and arriving at the Port of Seattle in 18 days. Providing speed and predictability, the bi-weekly service offers the fastest trip from Vietnam to the US. This revolutionary agreement is the first dedicated ocean service by an NVOCC in the trade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006070/en/
“Customers have been asking for creative solutions during this extremely challenging market, and this first-of-its-kind service is part of our response. Congestion and rate spikes will come and go, but the root issues remain. US importers are pushing for more creativity and controlled reliable solutions to manage supply chain risk,” UWL President Duncan Wright said.
The service offers priority berthing at both origin and destination, and a dedicated equipment pool for suppliers in Ho Chi Minh City. This includes 6,000 brand-new ocean containers, with 40-foot-high cube and 20-foot containers already in the rotation. Predictability is assured, as schedules are published six months in advance, with two sailings per month.
Upon arrival in Seattle, those needing warehousing or distribution space can take advantage of UWL’s sister company, World Distribution Services (WDS), and its brand-new 300,000 sq. ft. facility near Tacoma, WA, just a short drive away from the Port of Seattle.
“In joining forces with UWL, an innovative and integrated logistics provider to American BCOs, we are confident that our ocean express solution will be compelling to importers and exporters who need a direct port-to-port, fast, and reliable service between Vietnam and the Pacific Northwest,” said Rufus Frere-Smith, Regional Head, Americas, Swire Shipping, which facilitates trade in more than 90 countries and across 400 ports. “Our partnership is built on a joint vision of responding to customers’ desire for reliable, safe, and innovative shipping solutions.”
Mr. Wright noted: “We have seen incredibly strong demand for this service already, which tells us that fast and reliable niche services are here to stay. Our relationship with Swire Shipping is critical to making all this work. Their remarkable 150-year history and robust knowledge of ocean shipping and strong Asia legacy, combined with UWL’s culture of innovation, brings this dedicated service to life.”
Mr. Frere-Smith commented: “We have deployed new state-of-the-art, fuel-efficient vessels that will sail at high speed, safely and sustainably. We are confident customers and BCOs will find this direct, express service to be extremely effective in shipping their high value products and getting to market quickly.”
About UWL
UWL is a top 10 American-owned NVOCC and leading provider of global 3PL services. They take pride in delivering seamless supply chain solutions backed by a team of creative problem-solvers. Specializing in ocean transportation, air freight, road and rail, warehousing and distribution, project cargo, and customs house brokerage, their proof is in owned assets: a national network of distribution centers, dependable trucking capacity, and WorldScope , a user-friendly data management platform that delivers transparency and visibility customers can count on. Wherever your freight needs to go, they can help get it there. To find out more, visit their website at www.shipuwl.com
About Swire Shipping
Swire Shipping is a privately owned organization that was founded in 1872 and now comprises over 600 employees in 20 countries and owns and deploys over 30 vessels in the intra-Asia, Australasia, and Polynesia trades. It is part of the Swire Group which is a Hong Kong- and London-based British conglomerate. Many of its core businesses can be found within the Asia Pacific region, where traditionally Swire’s operations have centered on Hong Kong and mainland China. Its subsidiaries include Cathay Pacific Airlines, Swire Properties, China Navigation Company, Swire Hotels and Swire Resources.
About World Group
World Group was founded over 60 years ago as a pioneer in vessel agency services on the Great Lakes. Today, they are home to a portfolio of globally trusted brands that deliver customers end-to-end supply chain and logistics solutions, including ContainerPort Group, UWL, World Distribution Services, and World Shipping, Inc. With industry-leading products in ocean drayage and domestic trucking, freight forwarding and air freight, customs house brokerage, vessel husbandry, and warehousing and distribution, customers around the globe use their services to simplify supply chains and reliably move freight.
Offering career opportunities across the country for innovators in the transportation industry, their award-winning culture is anchored in people who live and breathe the company’s core values daily. Learn how to join the World Group family by visiting their careers page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom